Variables | Response | p | |
---|---|---|---|
PR (n = 13) | CR (n =17) | ||
Age (years) | Â | Â | 0.177 |
 <60 | 10 (76.9%) | 9 (52.9%) |  |
 ≥60 | 3 (23.1%) | 8 (47.1%) |  |
FIGO stage | Â | Â | 0.030 * |
 I~II | 4 (30.8%) | 12 (70.6%) |  |
III~IV | 9 (69.2%) | 5 (29.4%) | Â |
Tumor size (cm) | Â | Â | 0.020 * |
 <4 | 1 (7.7%) | 8 (47.1%) |  |
 ≥4 | 12 (92.3%) | 9 (52.9%) |  |
LNs metastasis | Â | Â | 0.153 |
 Negative | 5 (38.5%) | 11 (64.7%) |  |
 Positive | 8 (61.5%) | 6 (35.3%) |  |
Pre-NLR | Â | Â | 0.009 * |
 Low | 1 (7.7%) | 9 (52.9%) |  |
 High | 12 (92.3%) | 8 (47.1%) |  |
Pre-PNR | Â | Â | 0.225 |
 Low | 9 (69.2%) | 8 (47.1%) |  |
 High | 4 (30.8%) | 9 (52.9%) |  |
Pre-PLR | Â | Â | 0.004 * |
 Low | 4 (30.8%) | 14 (82.4%) |  |
 High | 9 (69.2%) | 3 (17.6%) |  |
Pre-LMR | Â | Â | 0.003 * |
 Low | 7 (53.8%) | 1 (5.9%) |  |
 High | 6 (46.2%) | 16 (94.1%) |  |
10F-NLR | Â | Â | 0.127 |
 Low | 4 (30.8%) | 10 (58.8%) |  |
 High | 9 (69.2%) | 7 (41.2%) |  |
10F-PNR | Â | Â | 0.012 * |
 Low | 4 (30.8%) | 13 (76.5%) |  |
 High | 9 (69.2%) | 4 (23.5%) |  |
10F-PLR | Â | Â | 0.013 * |
 Low | 6 (46.2%) | 15 (88.2%) |  |
 High | 7 (53.8%) | 2 (11.8%) |  |
10F-LMR | Â | Â | 0.004 * |
 Low | 10 (76.9%) | 4 (23.5%) |  |
 High | 3 (23.1%) | 13 (76.5%) |  |
Immune score, median (interquartile range) | 0.042 (-0.264 to 0.278) | 0.548 (0.416 to 0.749) | 0.002 * |